In a former life ImmunoCellular Therapeutics Ltd (IMUC) was a biotechnology company focusing on cancer immunotherapy, now its just a cash shell with some potential.
Apologies for the lack of activity on the blog in recent weeks, I've been busy working with my friend @Jansvenda to produce an updated version of the Svenda's Manual of OTC stocks.
PHSC plc (PHSC) is a £1.25 Mil market cap firm trading on the AIM market of the LSE. It has current assets and PPE of £1.79 Mil net of Total Liabilities. At this price you get the operating businesses for free.
FullNet Communications Inc (FULO) is a tiny company trading on the pink-sheets, the float is low and it's shares are thinly traded. In some ways it is cheap, in others maybe not. Much like every other company I write up it's got plenty of hair on it .
Getech PLC (GTC:LON) is a tiny little firm floating on the AIM market of the LSE. It currently languishes just above it's all time low and market sentiment toward the company is unequivocally bearish. Sounds like my kind of company.
My friend, Jan Svenda, has recently released an updated version of his OTC manual at a discounted price. The manual now includes 2019 updates, financials for 36 'dark' companies and a lower price, down from $399 to $149.
I like to use this manual to generate ideas and to see Jan's opinion of OTC stocks I have found myself, it's also useful to look up stocks from the old Walker's manuals to see if the companies are still in business and how they are performing.
Over to Jan with a bit more info.
Nuvectra Corp. (NVTRQ) commenced Chpt. 11 bankruptcy proceedings on November 12th 2019. The share price took a nose dive from $1.39 to $0.22, since then it's been trading in the $0.10-0.20 range.
Upon first glance it looks like game over for the common, but sometimes looks can be deceiving.
Myrexis Inc. (MYRX) is another NOL stub controlled by Johnathan Couchman. Much like AFFY, it's tiny, thinly traded and has significant upside potential.
Affymax (AFFY) is a non-operating shell company which trades on the OTC markets. In a former life it was a bio-pharmaceutical firm engaged in the development of OMONTYS (peginesatide), a injection delivered pharma product for the treatment of anemia.
Origen Financial Inc (ORGN) is the first in a number of NOL stubs I'll be writing up here on the blog. It will come as no surprise to my regular readers that ORGN is a minuscule firm and it's stock is illiquid., just how I like 'em.
David J. Flood
UK based Value Investolator. I focus on Net-nets, Nano caps, OTC/Dark stocks & Special Situations. Balance sheets & Long-range price charts are my guide. Caveat Emptor!
BLOGS I FOLLOW
No Name Stocks
Svenda's Manual of OTC Stocks
Nothing But Net Nets
Clark Street Value
Value Investing Blog
Deep Value Investments
Value Stock Geek
Barel Karsan - Value Investing
Yet Another Value Blog
Streets Of Value
TES Optimal Value Investing
The Bad Investor
Adventures in Capitalism
White Chip Stocks
Light Blue Value
Global Investing Insight
Mesaba Range Value
The Market Plunger
Battleship Investing Blog
The Investment Long-List
Grahamian Value Digest
Canadian Value Stocks
Analyzing Bargain Stocks